SLC7A11 and lung carcinoma: Mutation of the SOX2 binding site in the SLC7A11 promoter enhances cancer cell sensitivity to ferroptosis, proposing SLC7A11 as a potential therapeutic target for lung cancer treatment (Wang et al., 2021c).